AtriCure (ATRC) Set to Announce Earnings on Wednesday

AtriCure (NASDAQ:ATRC - Get Free Report) will announce its earnings results after the market closes on Wednesday, May 1st. Analysts expect the company to announce earnings of ($0.20) per share for the quarter. Parties that wish to register for the company's conference call can do so using this link.

AtriCure (NASDAQ:ATRC - Get Free Report) last posted its earnings results on Thursday, February 15th. The medical device company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.01. The company had revenue of $106.50 million during the quarter, compared to analyst estimates of $103.68 million. AtriCure had a negative return on equity of 7.55% and a negative net margin of 7.62%. The business's revenue was up 21.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.09) earnings per share. On average, analysts expect AtriCure to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AtriCure Price Performance

NASDAQ ATRC traded down $0.12 on Wednesday, reaching $23.05. 419,955 shares of the stock traded hands, compared to its average volume of 682,192. The company has a quick ratio of 2.66, a current ratio of 3.57 and a debt-to-equity ratio of 0.15. AtriCure has a 12 month low of $22.27 and a 12 month high of $59.61. The company has a market cap of $1.12 billion, a price-to-earnings ratio of -34.92 and a beta of 1.38. The firm's fifty day simple moving average is $30.25 and its 200 day simple moving average is $33.84.

Insider Buying and Selling at AtriCure

In related news, insider Justin J. Noznesky sold 1,500 shares of the stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $36.72, for a total value of $55,080.00. Following the sale, the insider now owns 74,284 shares in the company, valued at $2,727,708.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, insider Justin J. Noznesky sold 1,500 shares of the firm's stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $36.72, for a total value of $55,080.00. Following the sale, the insider now directly owns 74,284 shares of the company's stock, valued at $2,727,708.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Karl S. Dahlquist sold 1,885 shares of the firm's stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $32.16, for a total value of $60,621.60. Following the completion of the sale, the insider now directly owns 50,954 shares in the company, valued at $1,638,680.64. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,116 shares of company stock valued at $468,797. Company insiders own 3.20% of the company's stock.

Wall Street Analysts Forecast Growth

ATRC has been the subject of several research reports. Stifel Nicolaus reduced their price target on AtriCure from $50.00 to $42.00 and set a "buy" rating for the company in a report on Friday, February 16th. Oppenheimer raised AtriCure from a "market perform" rating to an "outperform" rating and set a $32.00 price objective on the stock in a research note on Tuesday. Needham & Company LLC restated a "buy" rating and set a $46.00 target price on shares of AtriCure in a research report on Wednesday, April 10th. UBS Group upped their price objective on AtriCure from $57.00 to $58.00 and gave the company a "buy" rating in a report on Friday, February 16th. Finally, StockNews.com downgraded AtriCure from a "hold" rating to a "sell" rating in a report on Wednesday, March 27th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company's stock. According to data from MarketBeat.com, AtriCure presently has a consensus rating of "Moderate Buy" and an average target price of $52.63.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.